Abstract: Disclosed is a pharmaceutical composition containing obovatol represented by Formula 1 and its derivatives. The obovatol and its derivatives effectively increase the activity of AMPK (AMP-activated protein kinase) that plays an important role in diabetes and metabolic syndrome, and thus may be variously used in treating diabetes and metabolic syndrome. (In Formula 1, R1, R2 and R3 are the same as defined above).

Abstract: Disclosed herein are a novel cinnamaldehyde compound represented by Chemical Formula 1 or pharmaceutically acceptable salts thereof. The cinnamaldehyde compound has improved solubility in water and has inhibitory effects on the growth of cancer cells because it induces cell cycle arrest and cell death. Also disclosed are a method of preparing the cinnamaldehyde compound and an anticancer composition including the compound of Chemical Formula 1.

Abstract: The present invention relates to a high throughput screening method of a binding inhibitor between caspase3 and xIAP and chromomycin screened using the same, and more specifically, the present invention provides a method for screening anticancer substance, the method comprising the steps of reacting caspase3 or xIAP and candidate inhibitors of the binding between caspase3 and xIAP on a biochip for detecting caspase3:xIAP interaction, and selecting a candidate substance inhibiting the binding of caspase3 to xIAP as an anticancer substance, and an anticancer agent inhibiting caspase3:xIAP binding, which is screened by the above method. According to present invention, it is possible to develop a target-oriented anticancer agent focused on xIAP and caspase3, apoptosis-related proteins and thus it can be applied to tailored medication and combination therapy.

Abstract: The present invention relates to a composition for the prevention and treatment of inflammatory disease containing the extracts of Magnolia obovata or fractions thereof as an active ingredient, more precisely, a composition for the prevention and treatment of inflammatory disease containing the extracts of Magnolia obovata fruits and floral buds extracted with alcohol or alcohol aqueous solution as a solvent and active fractions isolated from the same. The extracts and fractions of the present invention inhibit lipopolysaccharide (LPS) induced nitric oxide (NO) generation significantly, have anti-inflammation activity and low cytotoxicity, and contain all of major effective components isolated from Magnolia obovata such as obovatol, honokiol and magnolol, so that they can be effectively used for the prevention and treatment of inflammatory disease.

Abstract: The present invention relates to a composition containing the extracts of Magnolia obovata Thunberg or fractions thereof for the prevention and treatment of cancer and for the inhibition of metastasis. Particularly, the extracts of Magnolia obovata Thunberg fruits and floral buds extracted with water, alcohol or a mixture thereof as a solvent and fractions isolated from the same inhibit metastasis by inhibiting migration of those cells over-expressing PRL-3 which plays an important role in cancer cell growth and migration and at the same time induce apoptosis of cancer cells, so that they can be effectively used as a composition for the prevention and treatment of cancer or a composition for the inhibition of metastasis.

Abstract: Disclosed herein are novel obovatol derivatives represented by Chemical Formula 1, and pharmaceutically acceptable salts thereof. Having the ability to inhibit the growth of cancer cells and induce apoptosis in cancer cells, the derivatives or pharmaceutically acceptable salts thereof are useful in the prevention and treatment of cancer and in the suppression of cancer metastasis. Also, a method for preparing the derivatives, and pharmaceutical compositions comprising the derivatives as active ingredients are disclosed. wherein R1,R2 and R3 are as defined in the specification.

Abstract: Disclosed herein is an anticancer composition, comprising obovatol, represented by the following Chemical Formula 1, obovatal, represented by the following Chemical Formula 2, and/or pharmaceutical salts thereof. The composition exhibits the activity of inhibiting the growth of cancer cells and suppressing the expression and activity of matrix metalloproteinases (MMPs), and thus can be useful for the prophylaxis and treatment of cancer as well as for the inhibition of cancer metastasis.

Abstract: The present invention relates to obovatol compound isolated from Magnolia obovata Thunb. for the prevention and treatment of anxiety disorders involved with CNS. The obovatol compound isolated from Magnolia obovata Thunb. have potent anti-anxiety activity, verified by an increased percentage of time on the open arms, an increased number of entries into, time spent on, the distal portion of the open arms, and a decreased activity of locomotor. Therefore it can be used as the therapeutics or health care food for treating and preventing anxiety disorders.

Abstract: Disclosed herein is a pharmaceutical composition for the prevention and treatment of restenosis following a blood vessel injury procedure, comprising obovatol as an active ingredient.

Abstract: Disclosed herein is an agent for preventing and treating cancer comprising an oxadiazole urea compound represented by Chemical Formula 1, below, as an effective ingredient. The oxadiazole urea compound effectively inhibits the growth of cancer cell lines and the activity of STAT3, and may be thus useful in the prevention and treatment of cancer.

Abstract: Disclosed herein a pharmaceutical composition, comprising obovatol as an active ingredient, for the prevention and treatment of neurodegenerative diseases. Having superior inhibitory activity against the production of neurotoxic nitric oxides, the obovatol isolated and purified from Magnoliaceae can be used as active ingredient for a pharmaceutical composition or a neuroprotective agent for the prevention and treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and the treatment of cancers containing diaryl-isoxazole derivatives as an effective ingredient. Diaryl-isoxazole derivatives of the present invention inhibit metastasis of breast cancer cell lines and angiogenesis, so that they can be produced as a metastasis inhibitor and further as a pharmaceutical composition for the prevention and the treatment of angiogenesis related diseases including cancers, rheumatoid arthritis, psoriasis, or angiogenesis diseases caused in eyeball, etc.

Abstract: Disclosed is a pharmaceutical composition for treating and preventing cancer, comprising a Cinnamoni Cortex extract and a Zizyphi Fructus extract. The pharmaceutical composition has effects of inducing apoptosis of cancer cells and inhibiting metastasis of cancer cells, as well as having a synergistic effect in inhibiting the growth of cancer cells compared to the separate use of the two extracts. Also, because the two extracts are extracted from natural origins, the pharmaceutical composition has no toxicity and is thus able to be used as a safe anticancer agent having excellent therapeutic efficacy. Further, the pharmaceutical composition is capable of being used as a functional food for preventing and treating cancer.

Abstract: Disclosed herein is an anticancer composition, comprising obovatol, represented by the following Chemical Formula 1, obovatal, represented by the following Chemical Formula 2, and/or pharmaceutical salts thereof. The composition exhibits the activity of inhibiting the growth of cancer cells and suppressing the expression and activity of matrix metalloproteinases (MMPs), and thus can be useful for the prophylaxis and treatment of cancer as well as for the inhibition of cancer metastasis.

Abstract: Disclosed is a composition for preventing cancer comprising a compound represented by Chemical Formula 1, 2?-benzoyloxycinnamaldehyde (BCA). BCA has the effects of delaying tumor incidence and increasing immune cells in a transgenic mouse overexpressing H-ras oncogene playing a critical role in tumor cell growth. Thus, BCA is useful as a cancer preventive drug.

Abstract: The present invention relates to cinnamaldehyde derivatives inhibiting growth of tumor cell and regulating cell cycle, the method for preparation and the pharmaceutical composition thereof. The cinnamaldehyde derivatives of the present invention can be effectively used as a cell cycle regulator or a cancer cell growth inhibitor, since it has an ability to regulate cell cycle by holding the cells in G2/M stage of the cell division and has activity to inhibit cancer cell growth.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and the treatment of cancers containing diaryl-isoxazole derivatives as an effective ingredient. Diaryl-isoxazole derivatives of the present invention inhibit metastasis of breast cancer cell lines and angiogenesis, so that they can be produced as a metastasis inhibitor and further as a pharmaceutical composition for the prevention and the treatment of angiogenesis related diseases including cancers, rheumatoid arthritis, psoriasis, or angiogenesis diseases caused in eyeball, etc.

Abstract: The present invention relates to cinnamaldehyde derivatives inhibiting growth of tumor cell and regulating cell cycle, the method for preparation and the pharmaceutical composition thereof. The cinnamaldehyde derivatives of the present invention can be effectively used as a cell cycle regulator or a cancer cell growth inhibitor, since it has an ability to regulate cell cycle by holding the cells in G2/M stage of the cell division and has activity to inhibit cancer cell growth.

Abstract: The present invention relates to a novel compound isolated from Artemisia Sylvatica, expressed by the formula 1, a method of isolation, and its use thereof, and more particularly to a novel compound isolated from Artemisia Sylvatica, a method of isolation, and its use in inhibiting farnesyl transferase activity, which is essential for activating Ras oncogene, and repressing cancer cell growth.

Abstract: The present invention relates to a novel compound isolated from Artemisia Sylvatica, expressed by the formula 1, a method of isolation, and its use thereof, and more particularly to a novel compound isolated from Artemisia Sylvatica, a method of isolation, and its use in inhibiting farnesyl transferase activity, which is essential for activating Ras oncogene, and repressing cancer cell growth.